Therapeutic targeting of the mitochondrial one-carbon pathway: perspectives, pitfalls, and potential

Li Na Zhao, Mikael Björklund, Matias J Caldez, Jie Zheng, Philipp Kaldis

Forskningsoutput: TidskriftsbidragÖversiktsartikelPeer review


Most of the drugs currently prescribed for cancer treatment are riddled with substantial side effects. In order to develop more effective and specific strategies to treat cancer, it is of importance to understand the biology of drug targets, particularly the newly emerging ones. A comprehensive evaluation of these targets will benefit drug development with increased likelihood for success in clinical trials. The folate-mediated one-carbon (1C) metabolism pathway has drawn renewed attention as it is often hyperactivated in cancer and inhibition of this pathway displays promise in developing anticancer treatment with fewer side effects. Here, we systematically review individual enzymes in the 1C pathway and their compartmentalization to mitochondria and cytosol. Based on these insight, we conclude that (1) except the known 1C targets (DHFR, GART, and TYMS), MTHFD2 emerges as good drug target, especially for treating hematopoietic cancers such as CLL, AML, and T-cell lymphoma; (2) SHMT2 and MTHFD1L are potential drug targets; and (3) MTHFD2L and ALDH1L2 should not be considered as drug targets. We highlight MTHFD2 as an excellent therapeutic target and SHMT2 as a complementary target based on structural/biochemical considerations and up-to-date inhibitor development, which underscores the perspectives of their therapeutic potential.

StatusPublished - 2021 mars 4

Ämnesklassifikation (UKÄ)

  • Neurovetenskaper


Utforska forskningsämnen för ”Therapeutic targeting of the mitochondrial one-carbon pathway: perspectives, pitfalls, and potential”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här